Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Key Takeaways Anti-amyloid drugs might be able to ward off Alzheimer’s diseaseIn a small group, such a drug cut Alzheimer’s symptom risk by 50%The drug was abandoned, but others are under ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Sabirnetug claims to be the first antibody to show selective engagement of amyloid beta oligomers (AβOs), a toxic form of amyloid beta that plays a critical role in the early stages of the illness.

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for ...

Although amyloid-beta is present in healthy brains ... However, until now, scientists have not investigated whether taking monoclonal antibody therapies could prevent or delay the onset of ...

Spatial transcriptomics on human brains parsed microglial reactions to amyloid immunotherapy. Both a vaccine and a therapeutic antibody summoned these cells to plaques. Responders expressed TREM2, ...

TUESDAY, March 25, 2025 (HealthDay News) — For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab, an anti-amyloid beta antibody, may delay clinical ...

Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...